Core Insights - Astrotech Corporation reported a significant increase in revenue for Q3 of fiscal year 2025, reaching $534 thousand compared to $50 thousand in the same quarter of fiscal year 2024, driven by TRACER 1000 shipments, a government grant, and recurring sales [6] - The company has launched four product lines aimed at various markets, including airport security, narcotics detection, and environmental monitoring, indicating a strong growth potential [2][4] - Astrotech's consolidated balance sheet shows a strong cash position with $20.9 million in cash and liquid investments, down from $31.9 million as of June 30, 2024, supporting ongoing R&D and marketing efforts [6] Financial Performance - For the three months ended March 31, 2025, the company reported a gross profit of $237 thousand, a significant increase from $8 thousand in the same period of the previous year [11] - Operating expenses totaled $4.1 million for Q3 2025, compared to $3.5 million in Q3 2024, leading to a loss from operations of $3.9 million [11] - The net loss for Q3 2025 was $3.6 million, compared to a net loss of $3.2 million in Q3 2024, reflecting ongoing investment in product development and market expansion [11] Recent Developments - Astrotech's subsidiary, 1st Detect, was awarded a research and development contract with the Department of Homeland Security to advance the TRACER 1000 for explosives trace detection [6] - The company established a new subsidiary, EN-SCAN, Inc., to focus on environmental testing applications, further diversifying its product offerings [6] - The TRACER 1000 NTD has been configured to screen for synthetic opiates and novel psychoactive substances, enhancing its capabilities in addressing the global drug crisis [6]

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are anticipated in mid-2025 Announced new $3M equity financing together with the previously reported $8.25M equity financing secures financial position into mid-2026 Promising pre-clinical data released for NPM-139 (semaglutide implant) for chronic weight management in obese and overweight patients Comp ...

Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell TherapyLONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the Company will exhibit four poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, which is being held from May 13-17, 2025, in New Orleans, LA. The posters will be avai ...

Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and first quarter 2025 financial results. The first quarter was largely dedicated to the initiation of a pivotal Phase 3 clinical trial in early AD, with the first participants entering the study on ...

Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis (FAP)Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of FAPGranted both Orphan Drug & Fast Track designations by FDA for Amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma (HCC) BRISBANE, Calif., May 1 ...

HOUSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc.™ (Nasdaq: SKWD) ("Skyward Specialty" or "the Company") a leader in the specialty property and casualty (P&C) market, announced today the Company has recruited Corey LaFlamme to assume the role of President, Captives & Specialty Programs, marking a key strategic move to support its continued growth in one of the fastest-expanding segments of the specialty market. Additionally, the Company announced that Kirby Hill, who has play ...

Revenue of $3.4 million in 1Q 2025 Domestication to U.S. Completed Awarded $30 Million Contract for AI-First Constellation and Closed $20 Million Registered Direct Offering NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Satellogic Inc. (NASDAQ: SATL), a leader in sub-meter resolution Earth Observation (“EO”) data collection, today provided a business update and reported its financial results for the three months ended March 31, 2025. “The year is off to a great start with our recent announcements in April relat ...

NOT FOR DISTRIBUTION IN THE UNITED STATES.FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW CALGARY, Alberta, May 13, 2025 (GLOBE NEWSWIRE) -- Alaris Equity Partners Income Trust (“Alaris” or the “Trust”) (TSX: AD.UN) is pleased to announce that it has entered into an agreement with a syndicate of underwriters (the “Underwriters”) led by National Bank Financial, CIBC Capital Markets and Desjardins Capital Markets, and including Acumen Capital Partners, Raymon ...

Core Insights - Avadel Pharmaceuticals has appointed Susan Rodriguez as Chief Operating Officer to lead the company's commercial strategy and operations, particularly in relation to the launch of LUMRYZ [1][2][17] - Rodriguez brings over 30 years of experience in the life sciences industry, having held leadership roles in various biopharmaceutical companies, which positions her well to support Avadel's growth and market expansion [2][17] Company Developments - LUMRYZ, an extended-release sodium oxybate medication, was approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness in adults with narcolepsy [3][5][17] - The FDA also approved LUMRYZ for pediatric patients aged 7 years and older on October 16, 2024, further expanding its market potential [3][5] Clinical and Regulatory Highlights - The approval of LUMRYZ was supported by the REST-ON™ Phase 3 trial, which demonstrated significant improvements in excessive daytime sleepiness, overall patient functioning, and cataplexy attacks compared to placebo [4][5] - LUMRYZ has been granted 7 years of Orphan Drug Exclusivity due to its clinical superiority over existing treatments, providing a once-nightly dosing regimen that enhances patient care [5][6] Market Position and Strategy - The company aims to scale operations to meet increasing patient demand for LUMRYZ, particularly in the narcolepsy community, and is exploring potential label expansion to include idiopathic hypersomnia [2][17] - Rodriguez's expertise in launching innovative therapies in rare diseases is expected to be instrumental in accelerating the growth of LUMRYZ and maximizing its market impact [2][17]

Core Viewpoint - FreightCar America, Inc. will participate in the Wolfe 18th Annual Global Transportation & Industrials Conference on May 20, 2025, indicating its engagement with investors and the industry [1]. Company Overview - FreightCar America is a diversified manufacturer and supplier of railroad freight cars, railcar parts, and components, headquartered in Chicago, Illinois [3]. - The company specializes in railcar repairs, complete railcar rebody services, and railcar conversions, which repurpose idled rail assets back into revenue service [3]. - Established in 1901, FreightCar America has built a reputation for quality railcars that are essential for economic growth and the North American supply chain [3].